Current and New Treatments for Fatty Liver Disease Linked to Metabolic Problems

Approximately one-third of the world's population is affected by metabolic dysfunction-associated steatotic liver disease (MASLD).

• Lifestyle modifications are critical yet challenging for managing MASLD.
• Resmetirom and semaglutide have recently been approved by the US FDA for treating metabolic dysfunction-associated steatohepatitis with fibrosis.
• Emerging therapeutic options show promising phase 3 data across various mechanisms of action.
• Non-pharmacological and pharmacological strategies are being explored to address MASLD.

Simplified